BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment. METHODS: We developed a sandwich ELISA using recombinant human PCSK9 protein and 2 affinity-purified polyclonal antibodies directed against human PCSK9. We measured circulating PCSK9 concentrations in 115 diabetic patients from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study before and after fenofibrate treatment. RESULTS: We found that plasma PCSK9 concentrations correlate with total (r = 0.45, P = 0.006) and LDL (r = 0.54, P = 0.001) cholesterol but not with triglycerides or HDL cholesterol concentrations in that cohort. After 6 weeks of treatment with comicronized fenofibrate (200 mg/day), plasma PCSK9 concentrations decreased by 8.5% (P = 0.041 vs pretreatment). This decrease correlated with the efficacy of fenofibrate, as judged by a parallel reduction in plasma triglycerides (r = 0.31, P = 0.015) and LDL cholesterol concentrations (r = 0.27, P = 0.048). CONCLUSIONS: We conclude that this decrease in PCSK9 explains at least in part the LDL cholesterol-lowering effects of fenofibrate. Fenofibrate might be of interest to further reduce cardiovascular risk in patients already treated with a statin.
BACKGROUND:Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment. METHODS: We developed a sandwich ELISA using recombinant humanPCSK9 protein and 2 affinity-purified polyclonal antibodies directed against humanPCSK9. We measured circulating PCSK9 concentrations in 115 diabeticpatients from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study before and after fenofibrate treatment. RESULTS: We found that plasma PCSK9 concentrations correlate with total (r = 0.45, P = 0.006) and LDL (r = 0.54, P = 0.001) cholesterol but not with triglycerides or HDL cholesterol concentrations in that cohort. After 6 weeks of treatment with comicronized fenofibrate (200 mg/day), plasma PCSK9 concentrations decreased by 8.5% (P = 0.041 vs pretreatment). This decrease correlated with the efficacy of fenofibrate, as judged by a parallel reduction in plasma triglycerides (r = 0.31, P = 0.015) and LDL cholesterol concentrations (r = 0.27, P = 0.048). CONCLUSIONS: We conclude that this decrease in PCSK9 explains at least in part the LDL cholesterol-lowering effects of fenofibrate. Fenofibrate might be of interest to further reduce cardiovascular risk in patients already treated with a statin.
Authors: Shelby Sullivan; Elisa Fabbrini; Jay D Horton; Kevin Korenblat; Bruce W Patterson; Samuel Klein Journal: Transl Res Date: 2011-07-19 Impact factor: 7.012
Authors: Bin Dong; Minhao Wu; Hai Li; Fredric B Kraemer; Khosrow Adeli; Nabil G Seidah; Sahng Wook Park; Jingwen Liu Journal: J Lipid Res Date: 2010-01-04 Impact factor: 5.922
Authors: Q Feng; W Q Wei; C P Chung; R T Levinson; L Bastarache; J C Denny; C M Stein Journal: Pharmacogenomics J Date: 2016-02-23 Impact factor: 3.550
Authors: Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh Journal: J Lipid Res Date: 2012-07-17 Impact factor: 5.922
Authors: Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder Journal: J Lipid Res Date: 2014-04-28 Impact factor: 5.922
Authors: Cristobal L Miranda; Valerie D Elias; Joshua J Hay; Jaewoo Choi; Ralph L Reed; Jan F Stevens Journal: Arch Biochem Biophys Date: 2016-03-11 Impact factor: 4.013
Authors: Susan G Lakoski; Thomas A Lagace; Jonathan C Cohen; Jay D Horton; Helen H Hobbs Journal: J Clin Endocrinol Metab Date: 2009-04-07 Impact factor: 5.958
Authors: David L Rainwater; Laura A Cox; Jeffrey Rogers; John L VandeBerg; Michael C Mahaney Journal: J Lipid Res Date: 2009-03-08 Impact factor: 5.922